Sermorelin

STARTING AT

Per Vial

Sermorelin is a peptide similar in structure to growth hormone-releasing hormone (GHRH).It stimulates the pituitary to release adequate amounts of growth hormone in concert with the body's circadian rhythm.

STARTING AT

Per Vial

ACTIVE INGREDIENTS
Sermorelin acetate
A synthetic peptide similar to the body's Growth Hormone Releasing Hormone
HOW TO USE
Suggested Dosing
Sermorelin Acetate 1 mg/mL (3 mL vial):
Inject 15 to 30 units (0.15-0.3 mL) subcutaneously nightly on an empty stomach for 5 out of 7 days per week.
Sermorelin Acetate 600 mcg Mini Troche:
Dissolve one troche buccally nightly on an empty stomach for 5 out of 7 days per week.
Sermorelin 1000 mcg/mL Nasal Spray:
Use 1 to 3 sprays nasally nightly for 5 out of 7 days a week. Use on an empty stomach.
DISCLAIMER
This compounded medication is only available when the commercially available product is unavailable or when a prescriber determines that there is a clinically significant difference for the patient.

Medicine Information

Potential Benefits

Improved non-REM sleep which may lead to healthier immune function
Support improved cognition, especially in the elderly
Enhanced tissue repair and recovery
Increased collagen production for healthier skin and nails
Improved libido
Support cardiovascular health
Improved insulin sensitivity
Enhanced ATP synthesis for better cellular energy regulation
Boosts physical performance
Increased bone mineral density
Increase in muscle mass paired with fat loss (improved body composition)

Treament Protocol

Legal

Storage Instructions

Warnings

Avoid in pregnancy or breastfeeding. There is insufficient safety data for use in these subpopulations.
Avoid use in patients with a current or past diagnosis of cancer, especially hormone-related tumors.
Medication may not provide a benefit in patients with chronic IGF-1 elevations.

Manufacturer Info

How It Works

Sermorelin acts on the somatotroph cells of the anterior pituitary gland to release growth hormone. The growth hormone (GH) is released within minutes of the onset of slow wave sleep. The amount of GH released in an episodic fashion is similar to the body's own physiological manner. GH triggers the release of IGF-1 from the liver. GH and IGF-1 work in concert and with the body's circadian rhythm to afford most of Sermorelin's benefits. Negative feedback to the hypothalamus-pituitary-GH axis by IGF-1 and another hormone, somatostatin, helps mitigate the downsides of excess GH. Sermorelin preserves the intricate feedback loops of the GH system and is notable for its safety profile amongst GH interventions, while providing numerous potential benefits .

F.A.Q

References

Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307-8. doi: 10.2147/ciia.2006.1.4.307. PMID: 18046908; PMCID: PMC2699646.

Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.

Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. Br J Pharmacol. 2008 Jun;154(3):557-68. doi: 10.1038/bjp.2008.153. PMID:18500379; PMCID: PMC2439518.

Sasanuma H, Nakata M, Parmila K, Nakae J, Yada T. PDK1-FoxO1 pathway in AgRP neurons of arcuate nucleus promotes bone formation via GHRH-GH-IGF1 axis. Mol Metab. 2017 Feb 17;6(5):428-439. doi: 10.1016/j.molmet.2017.02.003. PMID: 28462077; PMCID: PMC5404105.

Caicedo D, Díaz O, Devesa P, Devesa J. Growth Hormone (GH) and Cardiovascular System. Int J Mol Sci. 2018 Jan 18;19(1):290. doi: 10.3390/ijms19010290. PMID: 29346331; PMCID: PMC5796235.